Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Documents

  • e2265.full

    Final published version, 366 KB, PDF document

DOI

  • Viktoria Papp
  • Zsolt Illés, Syddansk Universitet
  • ,
  • Melinda Magyari, Rigshosp, University of Copenhagen, Danish Multiple Sclerosis Registry, Dept Neurol
  • ,
  • Nils Koch-Henriksen
  • Matthias Kant, Syddansk Universitet
  • ,
  • Claudia Christina Pfleger, Department of Neurology, Aalborg University Hospital, Denmark
  • ,
  • Shanu Faerch Roemer, Denmark
  • Michael Broksgaard Jensen, Københavns Universitet
  • ,
  • Annett Petersen, Syddansk Universitet
  • ,
  • Helle Hvilsted Nielsen
  • ,
  • Lene Rosendahl
  • ,
  • Z Mezei
  • ,
  • Tove Christensen
  • Kristina Bacher Svendsen
  • Poul Erik Hyldgaard Jensen
  • ,
  • Magnus Christian Lydolph, Københavns Universitet
  • ,
  • Niels Heegaard, Denmark
  • Jette Lautrup Frederiksen, Denmark
  • F. Sellebjerg, Denmark
  • Egon Stenager, Syddansk Universitet, Kolding), Sygehus Sønderjylland, Denmark
  • Thor Petersen

Objectives To estimate the nationwide population-based incidence, prevalence, and geographical distribution of neuromyelitis optica (NMO) spectrum disorder (NMOSD) in Denmark based on the 2015 International Panel for NMO Diagnosis (IPND) criteria. Methods We conducted a multicentre, historically prospective study. Data were sourced from the Danish National Patient Registry, the Danish Multiple Sclerosis Registry, departments of neurology, and laboratories providing aquaporin-4 antibody test. Cases were selected based on the 2006 Wingerchuk and the 2015 IPND criteria and were individually validated by an expert panel. Results We confirmed NMO in 30 cases (2006 criteria) and NMOSD in 56 cases (2015 IPND criteria) between 2007 and 2014. Defined by the 2006 criteria, the incidence of NMO was 0.029 per 100,000 person-years (95% confidence interval [CI] 0.014-0.051), and the prevalence (aged 16 years and older) was 0.566 per 100,000 (95% CI 0.370-0.830). Based on the 2015 IPND criteria, the incidence of NMOSD was 0.070 per 100,000 person-years (95% CI 0.046-0.102), and the prevalence (aged 16 years and older) was 1.09 per 100,000 (95% CI 0.808-1.440), without regional differences. Conclusions Our estimates of incidence and prevalence are similar to other Caucasian population-based studies using the 2015 IPND criteria. We found no geographical clustering in Denmark.

Original languageEnglish
JournalNeurology
Volume91
Issue24
Pages (from-to)E2265-E2275
Number of pages11
ISSN0028-3878
DOIs
Publication statusPublished - 11 Dec 2018

Bibliographical note

Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

    Research areas

  • DIAGNOSTIC-CRITERIA, MULTIPLE-SCLEROSIS

See relations at Aarhus University Citationformats

ID: 136347440